Novel anticarcinoembryonic antigen antibody-drug conjugate has antitumor activity in the existence of soluble antigen

被引：0
|
作者：
Shinmi, Daisuke [1 ]
Masuda, Kazuhiro [2 ]
机构：
[1] Kyowa Hakko Kirin Co Ltd, Antibody & Biol Res Labo, Tokyo, Japan
[2] Kyowa Hakko Kirin Co Ltd, Oncol Res Labo, Tokyo, Japan
来源：
CANCER SCIENCE | 2018年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
J-1101
引用
收藏
页码：332 / 332
页数：1
相关论文
共 50 条
  • [41] A novel human single-domain antibody-drug conjugate targeting CEACAM5 exhibits potent in vitro and in vivo antitumor activity
    Xiao-yi Zhu
    Quan-xiao Li
    Yu Kong
    Ke-ke Huang
    Gang Wang
    Yun-ji Wang
    Jun Lu
    Guo-qiang Hua
    Yan-ling Wu
    Tian-lei Ying
    Acta Pharmacologica Sinica, 2024, 45 : 609 - 618
  • [42] Belantamab mafodotin Antibody-drug conjugate targeting B-cell maturation antigen (BCMA) Treatment of multiple myeloma
    Routledge, D.
    DRUGS OF THE FUTURE, 2020, 45 (12) : 865 - 875
  • [43] A review of the novel tissue factor antibody-drug conjugate: Tisotumab vedotin
    Luu, Kevin
    Chu, Angelyne
    Chang, Brandon
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, : 441 - 449
  • [44] Preclinical development of a novel antibody-drug conjugate targeting "cold" tumors
    Kaplan, Angelo
    Attanasio, Nickolas
    Do, To Uyen T.
    Swaminathan, Sudha
    Bisht, Arnima
    Lou, San Lin
    Allen, Jason
    Boyd, Robert
    Ackroyd, James E.
    Feldman, Gleb
    Rohlff, Christian
    Dusek, Rachel L.
    CANCER RESEARCH, 2018, 78 (13)
  • [45] A novel antibody-drug conjugate targeting SAIL for the treatment of hematologic malignancies
    Kim, S. Y.
    Theunissen, J-W
    Balibalos, J.
    Liao-Chan, S.
    Babcock, M. C.
    Wong, T.
    Cairns, B.
    Gonzalez, D.
    van der Horst, E. H.
    Perez, M.
    Levashova, Z.
    Chinn, L.
    D'Alessio, J. A.
    Flory, M.
    Bermudez, A.
    Jackson, D. Y.
    Ha, E.
    Monteon, J.
    Bruhns, M. F.
    Chen, G.
    Migone, T-S
    BLOOD CANCER JOURNAL, 2015, 5 : e316 - e316
  • [46] Pharmacokinetic-Pharmacodynamic Modeling of the Antitumor Effects of SGN-CD19A, a Novel Antibody-Drug Conjugate, in Mice
    Zhao, Baiteng
    Stevison, Faith
    Law, Che-Leung
    Han, Tae H.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2013, 40 : S17 - S18
  • [47] YH013, a novel EGFR x MET bispecific antibody-drug conjugate, exhibits potent antitumor efficacy
    Han, Yanfei
    Shang, Chengzhang
    Li, Zhuon
    Han, Zhenyan
    Li, Jun
    Cui, Zixu
    An, Gao
    Hao, Wanjun
    Liu, Yujie
    Li, Hao
    Liu, Baihong
    Zhang, Ellen
    Lin, Qingcong
    Yang, Yi
    Shen, Yuelei
    CANCER RESEARCH, 2023, 83 (07)
  • [48] Antitumor effect of a novel humanized MUC1 antibody-drug conjugate on triple-negative breast cancer
    Li, Lan
    Cao, Jiawei
    Chen, Chunyan
    Qin, Yaqian
    He, Licai
    Gu, Haihua
    Wu, Guang
    HELIYON, 2023, 9 (04)
  • [49] Relationship between the intratumor pharmacokinetics and antitumor effect of the payload eribulin in the novel antibody-drug conjugate MORAb-202
    Koganemaru, S.
    Fuchigami, H.
    Tsugawa, H.
    Kuboki, Y.
    Furuuchi, K.
    Uenaka, T.
    Doi, T.
    Yasunaga, M.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S87 - S87
  • [50] Synergistic antitumor activity between HER2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer
    Liu, Hongfu
    Zhou, Dongdong
    Liu, Dongqin
    Xu, Xi
    Zhang, Kai
    Hu, Ruxia
    Xiong, Peng
    Wang, Changxin
    Zeng, Xiangfu
    Wang, Liefeng
    Zhang, Shuyong
    CELL DEATH & DISEASE, 2024, 15 (03)
12345